| Predicted Trait | |
| Reported Trait | Major depressive disorder |
| Mapped Trait(s) | major depressive disorder (MONDO_0002009) |
| Score Construction | |
| PGS Name | PRS_MDD |
| Development Method | |
| Name | SBayesR |
| Parameters | --ldm ldm_ukb_50k_bigset_2.8M\ --pi 0.95,0.02,0.02,0.01 \ --gamma 0.0,0.01,0.1,1 \ --chain-length 25000 \ --burn-in 5000 \ --out-freq 10 \ |
| Variants | |
| Original Genome Build | hg19 |
| Number of Variants | 1,773,528 |
| Effect Weight Type | NR |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000238 |
| Citation (link to publication) | Campos AI et al. Commun Med (Lond) (2021) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 322,580 individuals (100%) |
| PGS Evaluation | European: 100% 251 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST005902 Europe PMC: 29662059 |
322,580 individuals | European | NR |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM002681 | PSS001279| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Escitalopram takers | OR: 1.0 [0.92, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002682 | PSS001284| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Venlafaxine takers | OR: 1.05 [0.96, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002684 | PSS001281| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Mirtazapine takers | OR: 1.05 [0.91, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002685 | PSS001277| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Desvenlafaxine takers | OR: 1.01 [0.91, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002686 | PSS001276| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Citalopram takers | OR: 1.02 [0.9, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002687 | PSS001280| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Fluoxetine takers | OR: 1.06 [0.96, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002688 | PSS001278| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Duloxetine takers | OR: 1.06 [0.95, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002689 | PSS001282| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Paroxetine takers | OR: 1.08 [0.92, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002690 | PSS001243| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Sertraline takers | OR: 1.06 [0.98, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002691 | PSS001239| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Escitalopram takers | OR: 1.06 [0.98, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002692 | PSS001244| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Venlafaxine takers | OR: 1.01 [0.93, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002693 | PSS001235| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Amitriptyline takers | OR: 0.96 [0.83, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002694 | PSS001241| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Mirtazapine takers | OR: 1.07 [0.93, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002695 | PSS001237| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Desvenlafaxine takers | OR: 0.97 [0.87, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002696 | PSS001236| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Citalopram takers | OR: 0.99 [0.87, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002697 | PSS001240| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Fluoxetine takers | OR: 1.16 [1.04, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.41 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002698 | PSS001238| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Duloxetine takers | OR: 0.98 [0.88, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002699 | PSS001242| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Paroxetine takers | OR: 1.08 [0.93, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002700 | PSS001373| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Sertraline takers | OR: 1.03 [0.94, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002701 | PSS001369| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Escitalopram takers | OR: 1.01 [0.9, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002702 | PSS001374| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Venlafaxine takers | OR: 1.1 [1.0, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.18 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002703 | PSS001365| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Amitriptyline takers | OR: 0.99 [0.81, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002704 | PSS001371| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Mirtazapine takers | OR: 1.03 [0.86, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002705 | PSS001367| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Desvenlafaxine takers | OR: 1.04 [0.92, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002707 | PSS001370| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Fluoxetine takers | OR: 1.06 [0.95, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002708 | PSS001368| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Duloxetine takers | OR: 0.9 [0.79, 1.04] | — | Variance explained (Nagelkerke's R2*100): 0.21 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002709 | PSS001372| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Paroxetine takers | OR: 1.19 [1.0, 1.41] | — | Variance explained (Nagelkerke's R2*100): 0.53 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002710 | PSS001303| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Sertraline takers | OR: 1.13 [0.97, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.18 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002711 | PSS001299| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Escitalopram takers | OR: 0.96 [0.8, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002712 | PSS001304| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Venlafaxine takers | OR: 1.22 [1.03, 1.45] | — | Variance explained (Nagelkerke's R2*100): 0.51 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002713 | PSS001295| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Amitriptyline takers | OR: 1.06 [0.8, 1.4] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002715 | PSS001297| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Desvenlafaxine takers | OR: 1.0 [0.8, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002716 | PSS001296| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Citalopram takers | OR: 0.95 [0.72, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002717 | PSS001300| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Fluoxetine takers | OR: 1.3 [1.05, 1.6] | — | Variance explained (Nagelkerke's R2*100): 0.77 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002718 | PSS001298| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Duloxetine takers | OR: 0.99 [0.82, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002720 | PSS001263| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Sertraline takers | OR: 1.04 [0.98, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002721 | PSS001259| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Escitalopram takers | OR: 1.01 [0.94, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002722 | PSS001264| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Venlafaxine takers | OR: 0.98 [0.91, 1.05] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002723 | PSS001255| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Amitriptyline takers | OR: 1.06 [0.95, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002724 | PSS001261| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Mirtazapine takers | OR: 1.05 [0.94, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002725 | PSS001257| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Desvenlafaxine takers | OR: 1.09 [0.99, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002726 | PSS001256| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Citalopram takers | OR: 1.11 [1.0, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.23 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002727 | PSS001260| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Fluoxetine takers | OR: 1.0 [0.92, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002728 | PSS001258| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Duloxetine takers | OR: 1.03 [0.93, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002729 | PSS001262| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Paroxetine takers | OR: 0.98 [0.86, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002730 | PSS001403| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Sertraline takers | OR: 0.99 [0.92, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002731 | PSS001399| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Escitalopram takers | OR: 0.97 [0.89, 1.06] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002732 | PSS001404| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Venlafaxine takers | OR: 1.04 [0.96, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002733 | PSS001395| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Amitriptyline takers | OR: 1.14 [0.96, 1.37] | — | Variance explained (Nagelkerke's R2*100): 0.3 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002734 | PSS001401| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Mirtazapine takers | OR: 1.05 [0.9, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002735 | PSS001397| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Desvenlafaxine takers | OR: 0.99 [0.9, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002736 | PSS001396| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Citalopram takers | OR: 1.14 [0.99, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.29 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002737 | PSS001400| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Fluoxetine takers | OR: 1.04 [0.94, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002738 | PSS001398| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Duloxetine takers | OR: 0.96 [0.86, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002739 | PSS001402| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Paroxetine takers | OR: 1.1 [0.94, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.17 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002741 | PSS001309| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Escitalopram takers | OR: 1.06 [0.98, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002742 | PSS001314| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Venlafaxine takers | OR: 1.08 [1.0, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002743 | PSS001305| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Amitriptyline takers | OR: 1.12 [0.95, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002744 | PSS001311| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Mirtazapine takers | OR: 1.08 [0.93, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002745 | PSS001307| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Desvenlafaxine takers | OR: 1.06 [0.96, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002746 | PSS001306| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Citalopram takers | OR: 1.11 [0.99, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.24 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002747 | PSS001310| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Fluoxetine takers | OR: 1.06 [0.97, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002748 | PSS001308| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Duloxetine takers | OR: 1.16 [1.04, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.55 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002749 | PSS001312| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Paroxetine takers | OR: 1.1 [0.96, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.21 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002750 | PSS001423| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Sertraline takers | OR: 1.21 [1.03, 1.43] | — | Variance explained (Nagelkerke's R2*100): 0.44 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002751 | PSS001419| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Escitalopram takers | OR: 0.96 [0.78, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002752 | PSS001424| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Venlafaxine takers | OR: 1.14 [0.96, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002754 | PSS001421| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Mirtazapine takers | OR: 1.23 [0.88, 1.72] | — | Variance explained (Nagelkerke's R2*100): 0.45 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002755 | PSS001417| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Desvenlafaxine takers | OR: 1.08 [0.86, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002756 | PSS001416| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Citalopram takers | OR: 1.19 [0.87, 1.64] | — | Variance explained (Nagelkerke's R2*100): 0.32 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002757 | PSS001420| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Fluoxetine takers | OR: 1.01 [0.8, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002758 | PSS001418| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Duloxetine takers | OR: 1.09 [0.87, 1.35] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002759 | PSS001422| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Paroxetine takers | OR: 1.17 [0.86, 1.61] | — | Variance explained (Nagelkerke's R2*100): 0.3 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002760 | PSS001223| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Sertraline takers | OR: 1.15 [1.03, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.29 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002761 | PSS001219| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Escitalopram takers | OR: 1.16 [1.01, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.32 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002762 | PSS001224| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Venlafaxine takers | OR: 1.19 [1.07, 1.34] | — | Variance explained (Nagelkerke's R2*100): 0.54 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002763 | PSS001215| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Amitriptyline takers | OR: 1.16 [0.98, 1.37] | — | Variance explained (Nagelkerke's R2*100): 0.38 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002764 | PSS001221| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Mirtazapine takers | OR: 1.08 [0.89, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002765 | PSS001217| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Desvenlafaxine takers | OR: 1.03 [0.89, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002767 | PSS001220| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Fluoxetine takers | OR: 1.09 [0.94, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002768 | PSS001218| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Duloxetine takers | OR: 1.02 [0.89, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002769 | PSS001222| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Paroxetine takers | OR: 1.09 [0.9, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002771 | PSS001229| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Escitalopram takers | OR: 1.01 [0.89, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002772 | PSS001234| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Venlafaxine takers | OR: 1.13 [0.97, 1.32] | — | Variance explained (Nagelkerke's R2*100): 0.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002773 | PSS001225| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Amitriptyline takers | OR: 1.02 [0.73, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002774 | PSS001231| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Mirtazapine takers | OR: 1.13 [0.89, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.18 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002775 | PSS001227| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Desvenlafaxine takers | OR: 1.01 [0.84, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002776 | PSS001226| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Citalopram takers | OR: 0.95 [0.76, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002777 | PSS001230| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Fluoxetine takers | OR: 0.99 [0.84, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002778 | PSS001228| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Duloxetine takers | OR: 1.08 [0.9, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002779 | PSS001232| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Paroxetine takers | OR: 1.47 [1.13, 1.91] | — | Variance explained (Nagelkerke's R2*100): 1.92 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002780 | PSS001253| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Sertraline takers | OR: 1.01 [0.94, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002782 | PSS001254| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Venlafaxine takers | OR: 1.0 [0.91, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002783 | PSS001245| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Amitriptyline takers | OR: 0.99 [0.89, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002784 | PSS001251| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Mirtazapine takers | OR: 1.06 [0.96, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002785 | PSS001247| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Desvenlafaxine takers | OR: 0.99 [0.88, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002786 | PSS001246| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Citalopram takers | OR: 1.05 [0.93, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002787 | PSS001250| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Fluoxetine takers | OR: 1.04 [0.94, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002788 | PSS001248| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Duloxetine takers | OR: 0.96 [0.86, 1.08] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002789 | PSS001252| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Paroxetine takers | OR: 0.97 [0.83, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002790 | PSS001413| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Sertraline takers | OR: 1.04 [0.97, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002791 | PSS001409| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Escitalopram takers | OR: 1.02 [0.94, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002792 | PSS001414| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Venlafaxine takers | OR: 1.02 [0.94, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002793 | PSS001405| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Amitriptyline takers | OR: 1.05 [0.88, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002794 | PSS001411| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Mirtazapine takers | OR: 1.13 [0.97, 1.32] | — | Variance explained (Nagelkerke's R2*100): 0.27 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002795 | PSS001407| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Desvenlafaxine takers | OR: 1.05 [0.95, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002796 | PSS001406| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Citalopram takers | OR: 1.0 [0.89, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002797 | PSS001410| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Fluoxetine takers | OR: 1.05 [0.96, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002798 | PSS001408| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Duloxetine takers | OR: 0.97 [0.87, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002800 | PSS001203| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Sertraline takers | OR: 1.13 [1.04, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.29 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002801 | PSS001199| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Escitalopram takers | OR: 1.01 [0.91, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002802 | PSS001204| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Venlafaxine takers | OR: 1.14 [1.04, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.36 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002803 | PSS001195| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Amitriptyline takers | OR: 1.05 [0.87, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002804 | PSS001201| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Mirtazapine takers | OR: 1.2 [1.03, 1.39] | — | Variance explained (Nagelkerke's R2*100): 0.59 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002805 | PSS001197| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Desvenlafaxine takers | OR: 1.04 [0.92, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002806 | PSS001196| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Citalopram takers | OR: 0.97 [0.85, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002807 | PSS001200| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Fluoxetine takers | OR: 1.05 [0.96, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002808 | PSS001198| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Duloxetine takers | OR: 1.0 [0.87, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002809 | PSS001202| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Paroxetine takers | OR: 1.1 [0.94, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.19 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002810 | PSS001193| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Sertraline takers | OR: 1.04 [0.96, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002811 | PSS001189| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Escitalopram takers | OR: 1.06 [0.96, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002812 | PSS001194| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Venlafaxine takers | OR: 1.06 [0.97, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002813 | PSS001185| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Amitriptyline takers | OR: 1.02 [0.85, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002814 | PSS001191| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Mirtazapine takers | OR: 1.25 [1.08, 1.46] | — | Variance explained (Nagelkerke's R2*100): 0.93 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002816 | PSS001186| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Citalopram takers | OR: 1.05 [0.91, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002817 | PSS001190| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Fluoxetine takers | OR: 1.06 [0.96, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002818 | PSS001188| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Duloxetine takers | OR: 1.05 [0.91, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002819 | PSS001192| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Paroxetine takers | OR: 1.19 [1.02, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.6 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002820 | PSS001273| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Sertraline takers | OR: 1.01 [0.94, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002821 | PSS001269| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Escitalopram takers | OR: 0.96 [0.88, 1.05] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002822 | PSS001274| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Venlafaxine takers | OR: 1.06 [0.97, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002823 | PSS001265| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Amitriptyline takers | OR: 1.12 [0.97, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.25 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002824 | PSS001271| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Mirtazapine takers | OR: 1.06 [0.94, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002826 | PSS001266| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Citalopram takers | OR: 0.98 [0.86, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002827 | PSS001270| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Fluoxetine takers | OR: 1.02 [0.92, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002829 | PSS001272| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Paroxetine takers | OR: 0.96 [0.82, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002831 | PSS001429| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Escitalopram takers | OR: 1.04 [0.97, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002832 | PSS001434| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Venlafaxine takers | OR: 1.03 [0.96, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002833 | PSS001425| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Amitriptyline takers | OR: 1.06 [0.95, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002834 | PSS001431| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Mirtazapine takers | OR: 1.02 [0.93, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002835 | PSS001427| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Desvenlafaxine takers | OR: 1.11 [1.02, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.33 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002836 | PSS001426| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Citalopram takers | OR: 1.14 [1.03, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.4 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002837 | PSS001430| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Fluoxetine takers | OR: 1.04 [0.96, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002838 | PSS001428| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Duloxetine takers | OR: 1.0 [0.91, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002839 | PSS001432| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Paroxetine takers | OR: 1.11 [0.99, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.28 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002840 | PSS001443| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Sertraline takers | OR: 0.9 [0.75, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002841 | PSS001439| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Escitalopram takers | OR: 1.07 [0.88, 1.32] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002842 | PSS001444| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Venlafaxine takers | OR: 1.05 [0.84, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002844 | PSS001441| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Mirtazapine takers | OR: 1.21 [0.85, 1.71] | — | Variance explained (Nagelkerke's R2*100): 0.37 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002845 | PSS001437| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Desvenlafaxine takers | OR: 0.95 [0.74, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002846 | PSS001436| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Citalopram takers | OR: 0.87 [0.61, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.19 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002847 | PSS001440| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Fluoxetine takers | OR: 1.16 [0.96, 1.39] | — | Variance explained (Nagelkerke's R2*100): 0.26 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002848 | PSS001438| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Duloxetine takers | OR: 0.96 [0.75, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002849 | PSS001442| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Paroxetine takers | OR: 1.36 [0.88, 2.1] | — | Variance explained (Nagelkerke's R2*100): 0.99 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002852 | PSS001344| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Venlafaxine takers | OR: 1.0 [0.74, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002853 | PSS001335| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Amitriptyline takers | OR: 1.22 [0.73, 2.04] | — | Variance explained (Nagelkerke's R2*100): 0.42 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002854 | PSS001341| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Mirtazapine takers | OR: 1.0 [0.65, 1.52] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002855 | PSS001337| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Desvenlafaxine takers | OR: 1.58 [1.13, 2.23] | — | Variance explained (Nagelkerke's R2*100): 2.19 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002856 | PSS001336| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Citalopram takers | OR: 1.1 [0.7, 1.74] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002857 | PSS001340| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Fluoxetine takers | OR: 1.34 [0.91, 1.97] | — | Variance explained (Nagelkerke's R2*100): 0.75 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002858 | PSS001338| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Duloxetine takers | OR: 1.13 [0.75, 1.7] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002859 | PSS001342| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Paroxetine takers | OR: 1.16 [0.69, 1.95] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002860 | PSS001363| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Sertraline takers | OR: 1.0 [0.79, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002861 | PSS001359| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Escitalopram takers | OR: 0.91 [0.69, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002862 | PSS001364| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Venlafaxine takers | OR: 1.06 [0.8, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002863 | PSS001355| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Amitriptyline takers | OR: 0.59 [0.36, 0.98] | — | Variance explained (Nagelkerke's R2*100): 2.43 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002864 | PSS001361| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Mirtazapine takers | OR: 0.85 [0.55, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.25 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002865 | PSS001357| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Desvenlafaxine takers | OR: 0.8 [0.59, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.58 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002868 | PSS001358| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Duloxetine takers | OR: 0.99 [0.71, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002869 | PSS001362| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Paroxetine takers | OR: 0.9 [0.53, 1.52] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002870 | PSS001353| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Sertraline takers | OR: 1.0 [0.95, 1.06] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002871 | PSS001349| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Escitalopram takers | OR: 0.99 [0.93, 1.06] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002872 | PSS001354| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Venlafaxine takers | OR: 1.05 [0.99, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002873 | PSS001345| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Amitriptyline takers | OR: 1.08 [0.96, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.16 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002878 | PSS001348| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Duloxetine takers | OR: 0.99 [0.91, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002879 | PSS001352| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Paroxetine takers | OR: 1.0 [0.9, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002883 | PSS001205| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Amitriptyline takers | OR: 1.08 [0.86, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002884 | PSS001211| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Mirtazapine takers | OR: 1.05 [0.84, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002885 | PSS001207| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Desvenlafaxine takers | OR: 1.13 [0.94, 1.37] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002886 | PSS001206| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Citalopram takers | OR: 1.39 [1.08, 1.79] | — | Variance explained (Nagelkerke's R2*100): 1.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002887 | PSS001210| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Fluoxetine takers | OR: 1.03 [0.85, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002888 | PSS001208| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Duloxetine takers | OR: 1.04 [0.87, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002889 | PSS001212| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Paroxetine takers | OR: 1.32 [1.0, 1.75] | — | Variance explained (Nagelkerke's R2*100): 0.99 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002890 | PSS001393| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Sertraline takers | OR: 1.24 [1.14, 1.34] | — | Variance explained (Nagelkerke's R2*100): 0.9 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002894 | PSS001391| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Mirtazapine takers | OR: 1.09 [0.94, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002895 | PSS001387| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Desvenlafaxine takers | OR: 1.06 [0.94, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002896 | PSS001386| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Citalopram takers | OR: 1.06 [0.92, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002897 | PSS001390| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Fluoxetine takers | OR: 1.12 [1.02, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.27 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002898 | PSS001388| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Duloxetine takers | OR: 0.98 [0.86, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002899 | PSS001392| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Paroxetine takers | OR: 1.22 [1.05, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.8 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002900 | PSS001383| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Sertraline takers | OR: 1.15 [1.01, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.28 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002901 | PSS001379| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Escitalopram takers | OR: 1.06 [0.9, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002902 | PSS001384| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Venlafaxine takers | OR: 1.36 [1.18, 1.58] | — | Variance explained (Nagelkerke's R2*100): 1.35 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002903 | PSS001375| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Amitriptyline takers | OR: 0.97 [0.75, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002904 | PSS001381| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Mirtazapine takers | OR: 1.11 [0.88, 1.4] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002905 | PSS001377| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Desvenlafaxine takers | OR: 0.97 [0.78, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002906 | PSS001376| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Citalopram takers | OR: 0.96 [0.76, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002907 | PSS001380| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Fluoxetine takers | OR: 1.09 [0.95, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002908 | PSS001378| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Duloxetine takers | OR: 1.11 [0.89, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.15 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002909 | PSS001382| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Paroxetine takers | OR: 1.22 [0.95, 1.55] | — | Variance explained (Nagelkerke's R2*100): 0.54 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002910 | PSS001333| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Sertraline takers | OR: 0.99 [0.91, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002911 | PSS001329| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Escitalopram takers | OR: 0.96 [0.86, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002912 | PSS001334| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Venlafaxine takers | OR: 1.14 [1.03, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.31 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002913 | PSS001325| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Amitriptyline takers | OR: 1.07 [0.88, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002914 | PSS001331| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Mirtazapine takers | OR: 1.03 [0.87, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002915 | PSS001327| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Desvenlafaxine takers | OR: 1.02 [0.88, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002916 | PSS001326| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Citalopram takers | OR: 0.95 [0.82, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002917 | PSS001330| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Fluoxetine takers | OR: 1.05 [0.93, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002918 | PSS001328| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Duloxetine takers | OR: 1.04 [0.89, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002919 | PSS001332| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Paroxetine takers | OR: 0.97 [0.81, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002920 | PSS001323| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Sertraline takers | OR: 1.04 [0.89, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002921 | PSS001319| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Escitalopram takers | OR: 1.04 [0.89, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002922 | PSS001324| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Venlafaxine takers | OR: 0.94 [0.79, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002923 | PSS001315| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Amitriptyline takers | OR: 1.03 [0.84, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002924 | PSS001321| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Mirtazapine takers | OR: 1.05 [0.83, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002925 | PSS001317| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Desvenlafaxine takers | OR: 0.82 [0.68, 0.98] | — | Variance explained (Nagelkerke's R2*100): 0.6 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002680 | PSS001283| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Sertraline takers | OR: 1.03 [0.95, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002683 | PSS001275| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Amitriptyline takers | OR: 0.96 [0.81, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002706 | PSS001366| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Citalopram takers | OR: 1.16 [0.98, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.32 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002714 | PSS001301| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Mirtazapine takers | OR: 1.13 [0.9, 1.43] | — | Variance explained (Nagelkerke's R2*100): 0.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002719 | PSS001302| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Paroxetine takers | OR: 1.18 [0.87, 1.61] | — | Variance explained (Nagelkerke's R2*100): 0.34 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002740 | PSS001313| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Sertraline takers | OR: 1.08 [1.01, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.13 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002753 | PSS001415| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Amitriptyline takers | OR: 0.93 [0.65, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002766 | PSS001216| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Citalopram takers | OR: 1.02 [0.85, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002770 | PSS001233| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Sertraline takers | OR: 1.05 [0.94, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002781 | PSS001249| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Escitalopram takers | OR: 0.96 [0.89, 1.05] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002799 | PSS001412| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Paroxetine takers | OR: 1.06 [0.92, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002815 | PSS001187| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Desvenlafaxine takers | OR: 1.07 [0.94, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002825 | PSS001267| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Desvenlafaxine takers | OR: 1.02 [0.91, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002828 | PSS001268| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Duloxetine takers | OR: 0.93 [0.83, 1.04] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002830 | PSS001433| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Sertraline takers | OR: 1.02 [0.96, 1.08] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002843 | PSS001435| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Amitriptyline takers | OR: 1.09 [0.67, 1.78] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002850 | PSS001343| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Sertraline takers | OR: 1.04 [0.8, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002851 | PSS001339| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Escitalopram takers | OR: 1.09 [0.79, 1.5] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002866 | PSS001356| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Citalopram takers | OR: 1.05 [0.73, 1.51] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002867 | PSS001360| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Fluoxetine takers | OR: 1.03 [0.76, 1.4] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002874 | PSS001351| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Mirtazapine takers | OR: 0.99 [0.9, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002875 | PSS001347| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Desvenlafaxine takers | OR: 1.11 [1.02, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.34 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002876 | PSS001346| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Citalopram takers | OR: 1.1 [1.01, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.28 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002877 | PSS001350| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Fluoxetine takers | OR: 1.05 [0.98, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002880 | PSS001213| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Sertraline takers | OR: 0.96 [0.83, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002881 | PSS001209| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Escitalopram takers | OR: 1.03 [0.87, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002882 | PSS001214| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Venlafaxine takers | OR: 0.97 [0.84, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002891 | PSS001389| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Escitalopram takers | OR: 1.09 [0.99, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.15 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002892 | PSS001394| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Venlafaxine takers | OR: 1.19 [1.09, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.63 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002893 | PSS001385| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Amitriptyline takers | OR: 0.94 [0.8, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002926 | PSS001316| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Citalopram takers | OR: 1.08 [0.92, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002927 | PSS001320| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Fluoxetine takers | OR: 1.05 [0.91, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002928 | PSS001318| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Duloxetine takers | OR: 0.91 [0.74, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002929 | PSS001322| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Paroxetine takers | OR: 0.97 [0.77, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM038318 | PSS013916| European Ancestry| 425,240 individuals |
PGP000865 | Bhatt IS et al. J Assoc Res Otolaryngol (2024) |Ext. |
Reported Trait: Age-related hearing difficulty | β: 0.11966 | — | — | — | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS001185 | — | — | [
|
— | European | — | AGDS | — |
| PSS001186 | — | — | [
|
— | European | — | AGDS | — |
| PSS001187 | — | — | [
|
— | European | — | AGDS | — |
| PSS001188 | — | — | [
|
— | European | — | AGDS | — |
| PSS001189 | — | — | [
|
— | European | — | AGDS | — |
| PSS001190 | — | — | [
|
— | European | — | AGDS | — |
| PSS001191 | — | — | [
|
— | European | — | AGDS | — |
| PSS001192 | — | — | [
|
— | European | — | AGDS | — |
| PSS001193 | — | — | [
|
— | European | — | AGDS | — |
| PSS001194 | — | — | [
|
— | European | — | AGDS | — |
| PSS001195 | — | — | [
|
— | European | — | AGDS | — |
| PSS001196 | — | — | [
|
— | European | — | AGDS | — |
| PSS001197 | — | — | [
|
— | European | — | AGDS | — |
| PSS001198 | — | — | [
|
— | European | — | AGDS | — |
| PSS001199 | — | — | [
|
— | European | — | AGDS | — |
| PSS001200 | — | — | [
|
— | European | — | AGDS | — |
| PSS001201 | — | — | [
|
— | European | — | AGDS | — |
| PSS001202 | — | — | [
|
— | European | — | AGDS | — |
| PSS001203 | — | — | [
|
— | European | — | AGDS | — |
| PSS001204 | — | — | [
|
— | European | — | AGDS | — |
| PSS001205 | — | — | [
|
— | European | — | AGDS | — |
| PSS001206 | — | — | [
|
— | European | — | AGDS | — |
| PSS001207 | — | — | [
|
— | European | — | AGDS | — |
| PSS001208 | — | — | [
|
— | European | — | AGDS | — |
| PSS001209 | — | — | [
|
— | European | — | AGDS | — |
| PSS001210 | — | — | [
|
— | European | — | AGDS | — |
| PSS001211 | — | — | [
|
— | European | — | AGDS | — |
| PSS001212 | — | — | [
|
— | European | — | AGDS | — |
| PSS001213 | — | — | [
|
— | European | — | AGDS | — |
| PSS001214 | — | — | [
|
— | European | — | AGDS | — |
| PSS001215 | — | — | [
|
— | European | — | AGDS | — |
| PSS001216 | — | — | [
|
— | European | — | AGDS | — |
| PSS001217 | — | — | [
|
— | European | — | AGDS | — |
| PSS001218 | — | — | [
|
— | European | — | AGDS | — |
| PSS001219 | — | — | [
|
— | European | — | AGDS | — |
| PSS001220 | — | — | [
|
— | European | — | AGDS | — |
| PSS001221 | — | — | [
|
— | European | — | AGDS | — |
| PSS001222 | — | — | [
|
— | European | — | AGDS | — |
| PSS001223 | — | — | [
|
— | European | — | AGDS | — |
| PSS001224 | — | — | [
|
— | European | — | AGDS | — |
| PSS001225 | — | — | [
|
— | European | — | AGDS | — |
| PSS001226 | — | — | [
|
— | European | — | AGDS | — |
| PSS001227 | — | — | [
|
— | European | — | AGDS | — |
| PSS001228 | — | — | [
|
— | European | — | AGDS | — |
| PSS001229 | — | — | [
|
— | European | — | AGDS | — |
| PSS001230 | — | — | [
|
— | European | — | AGDS | — |
| PSS001231 | — | — | [
|
— | European | — | AGDS | — |
| PSS001232 | — | — | [
|
— | European | — | AGDS | — |
| PSS001233 | — | — | [
|
— | European | — | AGDS | — |
| PSS001234 | — | — | [
|
— | European | — | AGDS | — |
| PSS001235 | — | — | [
|
— | European | — | AGDS | — |
| PSS001236 | — | — | [
|
— | European | — | AGDS | — |
| PSS001237 | — | — | [
|
— | European | — | AGDS | — |
| PSS001238 | — | — | [
|
— | European | — | AGDS | — |
| PSS001239 | — | — | [
|
— | European | — | AGDS | — |
| PSS001240 | — | — | [
|
— | European | — | AGDS | — |
| PSS001241 | — | — | [
|
— | European | — | AGDS | — |
| PSS001242 | — | — | [
|
— | European | — | AGDS | — |
| PSS001243 | — | — | [
|
— | European | — | AGDS | — |
| PSS001244 | — | — | [
|
— | European | — | AGDS | — |
| PSS001245 | — | — | [
|
— | European | — | AGDS | — |
| PSS001246 | — | — | [
|
— | European | — | AGDS | — |
| PSS001247 | — | — | [
|
— | European | — | AGDS | — |
| PSS001248 | — | — | [
|
— | European | — | AGDS | — |
| PSS001249 | — | — | [
|
— | European | — | AGDS | — |
| PSS001250 | — | — | [
|
— | European | — | AGDS | — |
| PSS001251 | — | — | [
|
— | European | — | AGDS | — |
| PSS001252 | — | — | [
|
— | European | — | AGDS | — |
| PSS001253 | — | — | [
|
— | European | — | AGDS | — |
| PSS001254 | — | — | [
|
— | European | — | AGDS | — |
| PSS001255 | — | — | [
|
— | European | — | AGDS | — |
| PSS001256 | — | — | [
|
— | European | — | AGDS | — |
| PSS001257 | — | — | [
|
— | European | — | AGDS | — |
| PSS001258 | — | — | [
|
— | European | — | AGDS | — |
| PSS001259 | — | — | [
|
— | European | — | AGDS | — |
| PSS001260 | — | — | [
|
— | European | — | AGDS | — |
| PSS001261 | — | — | [
|
— | European | — | AGDS | — |
| PSS001262 | — | — | [
|
— | European | — | AGDS | — |
| PSS001263 | — | — | [
|
— | European | — | AGDS | — |
| PSS001264 | — | — | [
|
— | European | — | AGDS | — |
| PSS001265 | — | — | [
|
— | European | — | AGDS | — |
| PSS001266 | — | — | [
|
— | European | — | AGDS | — |
| PSS001267 | — | — | [
|
— | European | — | AGDS | — |
| PSS001268 | — | — | [
|
— | European | — | AGDS | — |
| PSS001269 | — | — | [
|
— | European | — | AGDS | — |
| PSS001270 | — | — | [
|
— | European | — | AGDS | — |
| PSS001271 | — | — | [
|
— | European | — | AGDS | — |
| PSS001272 | — | — | [
|
— | European | — | AGDS | — |
| PSS001273 | — | — | [
|
— | European | — | AGDS | — |
| PSS001274 | — | — | [
|
— | European | — | AGDS | — |
| PSS001275 | — | — | [
|
— | European | — | AGDS | — |
| PSS001276 | — | — | [
|
— | European | — | AGDS | — |
| PSS001277 | — | — | [
|
— | European | — | AGDS | — |
| PSS001278 | — | — | [
|
— | European | — | AGDS | — |
| PSS001279 | — | — | [
|
— | European | — | AGDS | — |
| PSS001280 | — | — | [
|
— | European | — | AGDS | — |
| PSS001281 | — | — | [
|
— | European | — | AGDS | — |
| PSS001282 | — | — | [
|
— | European | — | AGDS | — |
| PSS001283 | — | — | [
|
— | European | — | AGDS | — |
| PSS001284 | — | — | [
|
— | European | — | AGDS | — |
| PSS001295 | — | — | [
|
— | European | — | AGDS | — |
| PSS001296 | — | — | [
|
— | European | — | AGDS | — |
| PSS001297 | — | — | [
|
— | European | — | AGDS | — |
| PSS001298 | — | — | [
|
— | European | — | AGDS | — |
| PSS001299 | — | — | [
|
— | European | — | AGDS | — |
| PSS001300 | — | — | [
|
— | European | — | AGDS | — |
| PSS001301 | — | — | [
|
— | European | — | AGDS | — |
| PSS001302 | — | — | [
|
— | European | — | AGDS | — |
| PSS001303 | — | — | [
|
— | European | — | AGDS | — |
| PSS001304 | — | — | [
|
— | European | — | AGDS | — |
| PSS001305 | — | — | [
|
— | European | — | AGDS | — |
| PSS001306 | — | — | [
|
— | European | — | AGDS | — |
| PSS001307 | — | — | [
|
— | European | — | AGDS | — |
| PSS001308 | — | — | [
|
— | European | — | AGDS | — |
| PSS001309 | — | — | [
|
— | European | — | AGDS | — |
| PSS001310 | — | — | [
|
— | European | — | AGDS | — |
| PSS001311 | — | — | [
|
— | European | — | AGDS | — |
| PSS001312 | — | — | [
|
— | European | — | AGDS | — |
| PSS001313 | — | — | [
|
— | European | — | AGDS | — |
| PSS001314 | — | — | [
|
— | European | — | AGDS | — |
| PSS001315 | — | — | [
|
— | European | — | AGDS | — |
| PSS001316 | — | — | [
|
— | European | — | AGDS | — |
| PSS001317 | — | — | [
|
— | European | — | AGDS | — |
| PSS001318 | — | — | [
|
— | European | — | AGDS | — |
| PSS001319 | — | — | [
|
— | European | — | AGDS | — |
| PSS001320 | — | — | [
|
— | European | — | AGDS | — |
| PSS001321 | — | — | [
|
— | European | — | AGDS | — |
| PSS001322 | — | — | [
|
— | European | — | AGDS | — |
| PSS001323 | — | — | [
|
— | European | — | AGDS | — |
| PSS001324 | — | — | [
|
— | European | — | AGDS | — |
| PSS001325 | — | — | [
|
— | European | — | AGDS | — |
| PSS001326 | — | — | [
|
— | European | — | AGDS | — |
| PSS001327 | — | — | [
|
— | European | — | AGDS | — |
| PSS001328 | — | — | [
|
— | European | — | AGDS | — |
| PSS001329 | — | — | [
|
— | European | — | AGDS | — |
| PSS001330 | — | — | [
|
— | European | — | AGDS | — |
| PSS001331 | — | — | [
|
— | European | — | AGDS | — |
| PSS001332 | — | — | [
|
— | European | — | AGDS | — |
| PSS001333 | — | — | [
|
— | European | — | AGDS | — |
| PSS001334 | — | — | [
|
— | European | — | AGDS | — |
| PSS001335 | — | — | [
|
— | European | — | AGDS | — |
| PSS001336 | — | — | [
|
— | European | — | AGDS | — |
| PSS001337 | — | — | [
|
— | European | — | AGDS | — |
| PSS001338 | — | — | [
|
— | European | — | AGDS | — |
| PSS001339 | — | — | [
|
— | European | — | AGDS | — |
| PSS001340 | — | — | [
|
— | European | — | AGDS | — |
| PSS001341 | — | — | [
|
— | European | — | AGDS | — |
| PSS001342 | — | — | [
|
— | European | — | AGDS | — |
| PSS001343 | — | — | [
|
— | European | — | AGDS | — |
| PSS001344 | — | — | [
|
— | European | — | AGDS | — |
| PSS001345 | — | — | [
|
— | European | — | AGDS | — |
| PSS001346 | — | — | [
|
— | European | — | AGDS | — |
| PSS001347 | — | — | [
|
— | European | — | AGDS | — |
| PSS001348 | — | — | [
|
— | European | — | AGDS | — |
| PSS001349 | — | — | [
|
— | European | — | AGDS | — |
| PSS001350 | — | — | [
|
— | European | — | AGDS | — |
| PSS001351 | — | — | [
|
— | European | — | AGDS | — |
| PSS001352 | — | — | [
|
— | European | — | AGDS | — |
| PSS001353 | — | — | [
|
— | European | — | AGDS | — |
| PSS001354 | — | — | [
|
— | European | — | AGDS | — |
| PSS001355 | — | — | [
|
— | European | — | AGDS | — |
| PSS001356 | — | — | [
|
— | European | — | AGDS | — |
| PSS001357 | — | — | [
|
— | European | — | AGDS | — |
| PSS001358 | — | — | [
|
— | European | — | AGDS | — |
| PSS001359 | — | — | [
|
— | European | — | AGDS | — |
| PSS001360 | — | — | [
|
— | European | — | AGDS | — |
| PSS001361 | — | — | [
|
— | European | — | AGDS | — |
| PSS001362 | — | — | [
|
— | European | — | AGDS | — |
| PSS001363 | — | — | [
|
— | European | — | AGDS | — |
| PSS001364 | — | — | [
|
— | European | — | AGDS | — |
| PSS001365 | — | — | [
|
— | European | — | AGDS | — |
| PSS001366 | — | — | [
|
— | European | — | AGDS | — |
| PSS001367 | — | — | [
|
— | European | — | AGDS | — |
| PSS001368 | — | — | [
|
— | European | — | AGDS | — |
| PSS001369 | — | — | [
|
— | European | — | AGDS | — |
| PSS001370 | — | — | [
|
— | European | — | AGDS | — |
| PSS001371 | — | — | [
|
— | European | — | AGDS | — |
| PSS001372 | — | — | [
|
— | European | — | AGDS | — |
| PSS001373 | — | — | [
|
— | European | — | AGDS | — |
| PSS001374 | — | — | [
|
— | European | — | AGDS | — |
| PSS001375 | — | — | [
|
— | European | — | AGDS | — |
| PSS001376 | — | — | [
|
— | European | — | AGDS | — |
| PSS001377 | — | — | [
|
— | European | — | AGDS | — |
| PSS001378 | — | — | [
|
— | European | — | AGDS | — |
| PSS001379 | — | — | [
|
— | European | — | AGDS | — |
| PSS001380 | — | — | [
|
— | European | — | AGDS | — |
| PSS001381 | — | — | [
|
— | European | — | AGDS | — |
| PSS001382 | — | — | [
|
— | European | — | AGDS | — |
| PSS001383 | — | — | [
|
— | European | — | AGDS | — |
| PSS001384 | — | — | [
|
— | European | — | AGDS | — |
| PSS001385 | — | — | [
|
— | European | — | AGDS | — |
| PSS001386 | — | — | [
|
— | European | — | AGDS | — |
| PSS001387 | — | — | [
|
— | European | — | AGDS | — |
| PSS001388 | — | — | [
|
— | European | — | AGDS | — |
| PSS001389 | — | — | [
|
— | European | — | AGDS | — |
| PSS001390 | — | — | [
|
— | European | — | AGDS | — |
| PSS001391 | — | — | [
|
— | European | — | AGDS | — |
| PSS001392 | — | — | [
|
— | European | — | AGDS | — |
| PSS001393 | — | — | [
|
— | European | — | AGDS | — |
| PSS001394 | — | — | [
|
— | European | — | AGDS | — |
| PSS001395 | — | — | [
|
— | European | — | AGDS | — |
| PSS001396 | — | — | [
|
— | European | — | AGDS | — |
| PSS001397 | — | — | [
|
— | European | — | AGDS | — |
| PSS001398 | — | — | [
|
— | European | — | AGDS | — |
| PSS001399 | — | — | [
|
— | European | — | AGDS | — |
| PSS001400 | — | — | [
|
— | European | — | AGDS | — |
| PSS001401 | — | — | [
|
— | European | — | AGDS | — |
| PSS001402 | — | — | [
|
— | European | — | AGDS | — |
| PSS001403 | — | — | [
|
— | European | — | AGDS | — |
| PSS001404 | — | — | [
|
— | European | — | AGDS | — |
| PSS001405 | — | — | [
|
— | European | — | AGDS | — |
| PSS001406 | — | — | [
|
— | European | — | AGDS | — |
| PSS001407 | — | — | [
|
— | European | — | AGDS | — |
| PSS001408 | — | — | [
|
— | European | — | AGDS | — |
| PSS001409 | — | — | [
|
— | European | — | AGDS | — |
| PSS001410 | — | — | [
|
— | European | — | AGDS | — |
| PSS001411 | — | — | [
|
— | European | — | AGDS | — |
| PSS001412 | — | — | [
|
— | European | — | AGDS | — |
| PSS001413 | — | — | [
|
— | European | — | AGDS | — |
| PSS001414 | — | — | [
|
— | European | — | AGDS | — |
| PSS001415 | — | — | [
|
— | European | — | AGDS | — |
| PSS001416 | — | — | [
|
— | European | — | AGDS | — |
| PSS001417 | — | — | [
|
— | European | — | AGDS | — |
| PSS001418 | — | — | [
|
— | European | — | AGDS | — |
| PSS001419 | — | — | [
|
— | European | — | AGDS | — |
| PSS001420 | — | — | [
|
— | European | — | AGDS | — |
| PSS001421 | — | — | [
|
— | European | — | AGDS | — |
| PSS001422 | — | — | [
|
— | European | — | AGDS | — |
| PSS001423 | — | — | [
|
— | European | — | AGDS | — |
| PSS001424 | — | — | [
|
— | European | — | AGDS | — |
| PSS001425 | — | — | [
|
— | European | — | AGDS | — |
| PSS001426 | — | — | [
|
— | European | — | AGDS | — |
| PSS001427 | — | — | [
|
— | European | — | AGDS | — |
| PSS001428 | — | — | [
|
— | European | — | AGDS | — |
| PSS001429 | — | — | [
|
— | European | — | AGDS | — |
| PSS001430 | — | — | [
|
— | European | — | AGDS | — |
| PSS001431 | — | — | [
|
— | European | — | AGDS | — |
| PSS001432 | — | — | [
|
— | European | — | AGDS | — |
| PSS001433 | — | — | [
|
— | European | — | AGDS | — |
| PSS001434 | — | — | [
|
— | European | — | AGDS | — |
| PSS001435 | — | — | [
|
— | European | — | AGDS | — |
| PSS001436 | — | — | [
|
— | European | — | AGDS | — |
| PSS001437 | — | — | [
|
— | European | — | AGDS | — |
| PSS001438 | — | — | [
|
— | European | — | AGDS | — |
| PSS001439 | — | — | [
|
— | European | — | AGDS | — |
| PSS001440 | — | — | [
|
— | European | — | AGDS | — |
| PSS001441 | — | — | [
|
— | European | — | AGDS | — |
| PSS001442 | — | — | [
|
— | European | — | AGDS | — |
| PSS001443 | — | — | [
|
— | European | — | AGDS | — |
| PSS001444 | — | — | [
|
— | European | — | AGDS | — |
| PSS013916 | — | — | [ ,
46.21 % Male samples |
— | European (British, Irish) |
— | UKB | — |